BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $34.86 Million Holdings in Catalent, Inc. (NYSE:CTLT)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lowered its position in Catalent, Inc. (NYSE:CTLT) by 31.7% during the third quarter, according to its most recent filing with the SEC. The firm owned 575,446 shares of the company’s stock after selling 266,690 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Catalent were worth $34,855,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of CTLT. Millennium Management LLC lifted its holdings in Catalent by 129.2% in the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after buying an additional 2,299,784 shares during the period. ING Groep NV raised its position in shares of Catalent by 162.5% in the 3rd quarter. ING Groep NV now owns 1,130,504 shares of the company’s stock worth $68,475,000 after acquiring an additional 699,851 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Catalent in the 2nd quarter valued at about $29,172,000. Mizuho Markets Americas LLC bought a new stake in shares of Catalent during the 3rd quarter valued at about $30,285,000. Finally, Bank of Montreal Can grew its stake in Catalent by 222.0% during the second quarter. Bank of Montreal Can now owns 644,123 shares of the company’s stock worth $36,219,000 after purchasing an additional 444,084 shares during the period.

Catalent Stock Performance

Shares of CTLT stock opened at $60.98 on Friday. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The firm has a fifty day simple moving average of $59.79 and a two-hundred day simple moving average of $58.26. Catalent, Inc. has a 12 month low of $36.74 and a 12 month high of $61.50. The firm has a market capitalization of $11.07 billion, a PE ratio of -26.88, a price-to-earnings-growth ratio of 2.34 and a beta of 1.16.

Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the previous year, the firm earned ($0.10) earnings per share. The company’s revenue was up 4.2% on a year-over-year basis. Analysts forecast that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on CTLT shares. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Robert W. Baird reissued a “neutral” rating and set a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, StockNews.com cut shares of Catalent from a “hold” rating to a “sell” rating in a research report on Friday. One investment analyst has rated the stock with a sell rating and seven have issued a hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $63.40.

Insider Transactions at Catalent

In other news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,114 shares of company stock worth $305,931 in the last 90 days. Insiders own 0.31% of the company’s stock.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.